BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
23 juil. 2024 07h10 HE
|
BioRestorative Therapies, Inc
- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc....
BioRestorative Therapies Regains Compliance with Nasdaq Listing Rule 5250(c)(1); Reports First Quarter 2024 Financial Results
17 juin 2024 07h05 HE
|
BioRestorative Therapies, Inc
- Significant YoY improvement in operating performance - - Ends Q1-2024 with $16.4 million cash, cash equivalents, and marketable securities - MELVILLE, N.Y., June 17, 2024 (GLOBE NEWSWIRE) --...
BioRestorative Therapies in Substantive Discussions for Potential License Agreement for ThermoStem® Metabolic Disease Program
13 juin 2024 07h00 HE
|
BioRestorative Therapies, Inc
- Brown adipose derived stem cells with brown adipogenic potential would represent a new modality for the treatment of obesity and related metabolic disorders – - ThermoStem® is an off-the-shelf...
BioRestorative Therapies Announces Receipt of Nasdaq Non-Compliance Notice
24 mai 2024 19h45 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., May 24, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies Provides First Quarter 2024 Business Update
14 mai 2024 16h10 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., May 14, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
30 avr. 2024 16h15 HE
|
BioRestorative Therapies, Inc
- Company to provide update on exciting new commercial agreement, as well as Phase 2 clinical trial in Spine and preclinical development program in Obesity - MELVILLE, N.Y., April 30, 2024 (GLOBE...
BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology
30 avr. 2024 07h30 HE
|
BioRestorative Therapies, Inc
— Leading regenerative medicine and aesthetics innovators collaborate to build a vertically integrated, best-in-class biocosmeceutical platform — — Exclusive, five (5)-year agreement includes...
BioRestorative Therapies Announces Filing of 2023 Annual Report on Form 10-K
01 avr. 2024 07h45 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., April 01, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based...
BioRestorative Therapies to Participate in the 36th Annual ROTH Conference
11 mars 2024 16h15 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies,...
BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease
05 févr. 2024 07h30 HE
|
BioRestorative Therapies, Inc
— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company to host webcasted conference call today at 8:30am EST — MELVILLE, N.Y., Feb. 05,...